Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: glucagon like peptide-2 controlled release analogs - Entera Bio/OPKO health

X
Drug Profile

Research programme: glucagon like peptide-2 controlled release analogs - Entera Bio/OPKO health

Alternative Names: GLP-2 analogs - Entera Bio

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Entera Bio; OPKO Health
  • Developer Entera Bio
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Short bowel syndrome

Most Recent Events

  • 20 Mar 2024 Pharmacokinetic data from preclinical study in Short bowel syndrome released by Entera Bio
  • 12 Sep 2023 Entera Bio and OPKO Biologics enter into a research collaboration agreement to develop GLP-2 analogues
  • 05 May 2022 Entera Bio have patent protection related to the oral delivery of specific molecules or families of molecules, including parathyroid hormone (PTH), glucagon-like peptide (GLP)-1, GLP-2, human growth hormone (hGH), and others
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top